Form 8-K - Current report:
SEC Accession No. 0001193125-26-000907
Filing Date
2026-01-02
Accepted
2026-01-02 16:01:26
Documents
13
Period of Report
2025-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d90230d8k.htm   iXBRL 8-K 26046
2 EX-10.1 d90230dex101.htm EX-10.1 10645
  Complete submission text file 0001193125-26-000907.txt   150496

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20251230.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20251230_lab.xml EX-101.LAB 17233
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20251230_pre.xml EX-101.PRE 10812
15 EXTRACTED XBRL INSTANCE DOCUMENT d90230d8k_htm.xml XML 3515
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 26502310
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)